会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • ALDEHYDE-RELEASING COMPOUNDS
    • 甲醛释放化合物
    • WO0228345A3
    • 2007-11-29
    • PCT/AU0101254
    • 2001-10-05
    • UNIV TROBEUNIV BAR ILANUNIV TEL AVIVPHILLIPS DONALD RALPHCUTTS SUZANNE MARGARETREPHAELI ADANUDELMAN ABRAHAM
    • PHILLIPS DONALD RALPHCUTTS SUZANNE MARGARETREPHAELI ADANUDELMAN ABRAHAM
    • A61K31/19A61K31/203A61K31/21A61K31/53A61K45/06A61P35/00C07C59/125C07C59/305C07C69/003C07C69/28C07C69/36C07C69/40C07F9/09C12N15/12
    • A61K45/06C07C69/003C07C69/28C07C69/36C07C69/40
    • A method of treating cancer, comprising the step of administering to a subject in need thereof an effective amount of a compound or compounds which increase or supplement the intracellular levels of endogenous aldehyde, prior to, together with, or subsequent to the administration of a therapeutically-effective amount of a chemotherapeutic agent such as anthracyclines and anthracenediones, wherein the efficacy of the chemotherapeutic agent is enhanced relative to the efficacy of the chemotherapeutic agent alone. The compound may be an aldehyde-releasing compound (preferably formaldehyde), including known aldehyde-releasing compounds and two new classes of aldehyde-releasing compounds. One new class of aldehyde-releasing compounds of formula (II) release more than one equivalent of aldehyde Z-(L-M 1 -CHR-M 2 ) x (II) wherein x is an integer of 2 or more Z is a direct bond or a linking group of valency x; L is either a direct bond or a spacer group R is H or C1-4 alkyl, alkenyl or alkynyl; M 1 is a decomposable or hydrolysable group; and M 2 is a second decomposable or hydrolysable group. Another new class of aldehyde-releasing compounds include a radical based on an inhibitor of an aldehyde detoxifying agent, such as buthionine sulphoximine or crotonaldehyde.
    • 一种治疗癌症的方法,包括以下步骤:在有需要的受试者之前,在施用治疗性疾病之前,之后或之后施用有效量的增加或补充内源性醛的细胞内水平的化合物或化合物 - 化学治疗剂如蒽环类和蒽环类化合物的有效量,其中化疗剂的功效相对于单独的化学治疗剂的功效增强。 化合物可以是释放醛的化合物(优选甲醛),包括已知的释放醛的化合物和两种新类型的释放醛的化合物。 一类新的醛释放式(II)的化合物释放出多于一当量的醛Z-(LM 1 - )-CHR-M 2 O 2, (II)其中x是2或更大的整数Z是直接键或价数x的连接基团; L是直接键或间隔基R是H或C 1-4烷基,烯基或炔基; M 1是可分解的或可水解的基团; 和M 2是第二个可分解或可水解的基团。 另一种新的醛释放化合物包括基于醛解毒剂抑制剂的基团,例如丁硫氨酸亚磺酰亚胺或巴豆醛。
    • 4. 发明申请
    • METHOD AND SYSTEM FOR ENERGY MANAGEMENT
    • 用于能量管理的方法和系统
    • WO2011029137A3
    • 2011-07-07
    • PCT/AU2010001160
    • 2010-09-09
    • UNIV TROBEDESAI ANIRUDDHA ANILSINGH JUGDUTT
    • DESAI ANIRUDDHA ANILSINGH JUGDUTT
    • G06Q10/00G06Q50/00
    • G06Q10/06G06Q50/06H02J3/00H02J2003/003H02J2003/007
    • A method (300) of managing energy consumption associated with premises includes firstly generating (302) and storing an initial energy profile (304) of the premises. The profile (304) includes information characterising the premises, such as occupancy patterns, function of the premises, geographical location, installed appliances (108), and so forth. An expected energy usage (308) associated with the premises is computed over a predetermined time period based upon the information in the initial energy profile (304). Actual energy usage (312) associated with the premises is then recorded over the predetermined time period and the energy profile (304) is adaptively updated based upon the recorded energy usage (312). The energy profile (304) and the actual energy usage (312) are used to manage energy consumption associated with the premises. An installable system (100) and apparatus (102) for implementing the method at premises are also provided.
    • 管理与房屋相关联的能量消耗的方法(300)包括首先生成(302)并存储房屋的初始能量简档(304)。 简档(304)包括表征房屋的信息,诸如占用模式,房屋的功能,地理位置,安装的电器(108)等等。 基于初始能量分布图(304)中的信息在预定时间段上计算与房屋相关联的预期能量使用量(308)。 然后在预定时间段内记录与房屋相关联的实际能量使用(312),并且基于记录的能量使用(312)适应性地更新能量分布(304)。 能量简档(304)和实际能量使用(312)被用于管理与房屋相关的能量消耗。 还提供了用于在房屋中实施该方法的可安装系统(100)和设备(102)。
    • 5. 发明申请
    • ANTI-TUMOUR COMPOUNDS
    • 抗肿瘤化合物
    • WO0230906B1
    • 2002-06-13
    • PCT/AU0101265
    • 2001-10-09
    • UNIV TROBEAUCKLAND UNISERVICES LIMTEDDEADY LESLIE WILLIAMDENNY WILLIAM ALEXANDERBU XIANYONG
    • DEADY LESLIE WILLIAMDENNY WILLIAM ALEXANDERBU XIANYONG
    • A61K31/166A61K31/4184A61K45/06A61P35/00C07C235/84C07D221/08C07D221/18C07D231/54C07D239/70C07D471/06C07C229/12
    • C07D471/06A61K31/166A61K31/4184A61K45/06C07C235/84C07C2603/42C07D221/08C07D221/18C07D231/54C07D239/70A61K2300/00
    • A compound of formula (II) in which positional numbering, where mentioned, refers to the system illustrated above, and one or more W and one or more U are attached to a ring carbon or carbons at any of positions 1-11 or to a ring nitrogen at position 7 if present, and in which: W is C(=Q)NRCHJ(CH2)nR where Q is O or S, R is hydrogen or a C1-4 alkyl group which is optionally substituted with one or more OH or NH2 groups, J is H or a C1-C6 alkyl group optionally substituted with OH, OMe, NH2, NHMe or NMe2 functions, R is C(=NR )NH2, NHC(=NR )NH2 or NR R , where each of R and R are independently hydrogen or a C1-4 alkyl group which is optionally substituted with one or more OH or NH2 groups, and R and R are independently hydrogen or a C1-4 alkyl group which is optionally substituted with one or more OH or NH2 groups, or R and R together with the nitrogen atom to which they are attached form an optionally substituted saturated or unsaturated heterocyclic group; and n is an integer from 0 to 5; X, Y, V are independently CH or N; Z is CH2, CH-C1-4 alkyl, CO, O, S, SO, SO2, N-C1-4 alkyl or NH; and U is H, halo, OH, CO2H, NR R , nitro, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 aminoalkyl or C1-6 aminoalkoxy in which R and R have the same definitions as R and R above; or a pharmaceutically-acceptable salt, N-oxide, hydrate, solvate, pharmaceutically acceptable derivative, pro-drug, tautomer or isomer thereof, with the proviso that W at position 4 cannot be CONH(CH2)2NMe2, CONH(CH2)2NEt2, CONH(CH2)3NMe2, CONH(CH2)3NEt2, CONH(CH2)2Npiperidyl, or CONH(CH2)2Nmorpholinyl, when X and Y are N, V is CH, U is H and Z is CO. "Bis" compounds and carboxylic acid precursors are also claimed. The compounds are useful in the treatment of neoplastic conditions such as cancer.
    • 其中位置编号(其中提及的是上述系统)和一个或多个W和一个或多个U的位置编号的式(II)化合物与位于1-11任何位置的环碳或碳键连接至 其中:W为C(= Q)NRCHJ(CH2)nR 1其中Q为O或S,R为氢或任选被一个取代基取代的C 1-4烷基 或更多的OH或NH 2基团,J为H或任选被OH,OMe,NH 2,NHMe或NMe 2取代的C 1 -C 6烷基,R 1为C(= NR 2)NH 2,NHC(= NR NH 2或NR 4 R 5,其中R 2和R 3各自独立地为氢或任选被一个或多个OH或NH 2基团取代的C 1-4烷基, R 4和R 5独立地是氢或任选被一个或多个OH或NH 2基团取代的C 1-4烷基,或者R 4和R 5与氮原子一起被 它们连接形成任选取代的饱和或不饱和杂环 向上; n为0〜5的整数。 X,Y,V独立地为CH或N; Z是CH 2,CH-C 1-4烷基,CO,O,S,SO,SO 2,N-C 1-4烷基或NH; 并且U是H,卤素,OH,CO 2 H,NR 6 R 7,硝基,氰基,C 1-6烷基,C 1-6卤代烷基,C 1-6烷氧基,C 1-6卤代烷氧基,C 1-6氨基烷基或C 1 -6氨基烷氧基,其中R 6和R 7具有与上述R 4和R 5相同的定义; 或其药学上可接受的盐,N-氧化物,水合物,溶剂合物,药学上可接受的衍生物,前药物,互变异构体或异构体,条件是位置4处的W不能是CONH(CH2)2NMe2,CONH(CH2)2NEt2, CONH(CH2)3NMe2,CONH(CH2)3NEt2,CONH(CH2)2N哌啶基或CONH(CH2)2N吗啉基,当X和Y为N时,V为CH,U为H,Z为CO,“双” 酸性前体也被要求保护。 这些化合物可用于治疗肿瘤性疾病如癌症。